8-K: Perrigo Finalizes Sale of HRA Pharma Rare Diseases Business to Esteve Healthcare for Up to $275 Million

Perrigo Company plc has completed the divestment of its HRA Pharma Rare Diseases business to Esteve Healthcare, S.L. for a total consideration of up to 275 million.

Summary

• Perrigo has completed the sale of its HRA Pharma Rare Diseases business to Esteve Healthcare.
• The total consideration is up to 275 million, including a 190 million upfront cash payment and up to 85 million in potential earnout payments.
• The earnout payments are contingent on the Rare Diseases business achieving certain sales milestones.
• Perrigo intends to use the proceeds from the sale to repay debt.
• In 2023, the HRA Pharma Rare Diseases business generated approximately 50 million in net sales and 20 million in adjusted EBITDA.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful completion of the divestment and the planned use of proceeds for debt reduction. However, the loss of a revenue-generating business and the uncertainty of earnout payments temper the overall positivity.

Positives

• The divestment provides Perrigo with a significant cash infusion.
• The proceeds will be used to reduce debt, improving Perrigo's financial position.
• The sale allows Perrigo to focus on its core Consumer Self-Care Products business.
• The earnout structure provides potential for additional revenue based on the performance of the divested business.

Negatives

• Perrigo is losing a business that generated 50 million in net sales and 20 million in adjusted EBITDA in 2023.
• The earnout payments are not guaranteed and depend on the future performance of the divested business.

Risks

• The potential earnout payments are subject to the divested business achieving certain sales milestones, which may not be met.
• There is a risk that the costs or liabilities incurred or retained in connection with the transaction may exceed Perrigo's estimates.
• The company faces various risks including supply chain issues, economic conditions, and competition, which could impact future performance.

Future Outlook

Perrigo expects to redeploy proceeds from the divestment for debt repayment and the impact from this transaction was included in the company's previously issued 2024 outlook.

Industry Context

This divestment reflects a trend of pharmaceutical companies focusing on core business segments and divesting non-core assets. Perrigo's move to sell its Rare Diseases business aligns with its strategy to concentrate on Consumer Self-Care Products.

Comparison to Industry Standards

• The divestment of the HRA Pharma Rare Diseases business is comparable to other pharmaceutical companies streamlining their portfolios to focus on core competencies.
• The valuation of the transaction, with a total consideration of up to 275 million, is within the range of similar divestments in the pharmaceutical sector.
• The earnout structure is a common mechanism in such transactions, aligning the interests of both the buyer and the seller.
• The use of proceeds for debt repayment is a typical strategy for companies seeking to improve their financial health after a divestment.

Stakeholder Impact

• Shareholders will benefit from the debt reduction and focus on core business.
• Employees of the divested business will transition to Esteve Healthcare.
• Customers of the Rare Diseases business will now be served by Esteve Healthcare.

Next Steps

• Perrigo will redeploy the proceeds from the divestment for debt repayment.
• Perrigo will continue to focus on its core Consumer Self-Care Products business.

Key Dates

Keywords

Perrigo, HRA Pharma, Rare Diseases, Esteve Healthcare, Divestment, Acquisition, Merger, Sales, EBITDA, Debt Repayment, Consumer Self-Care Products, Pharmaceuticals